logo
United Healthcare, Memorial Sloan Kettering set to take contract squabbles to mediation

United Healthcare, Memorial Sloan Kettering set to take contract squabbles to mediation

CBS News9 hours ago

The clock is ticking on United Healthcare and Memorial Sloan Kettering Cancer Center to reach a contract agreement or thousands of patients could lose coverage for much-needed care.
CBS News New York spoke with one impacted woman who said it's a matter of life and death for many.
Deadlines to be aware of going forward
The current contract is in effect through June 30. If no deal is reached, Memorial Sloan Kettering says it will become out of network for most patients with United Healthcare or Oxford plans. However, New York has a 60-day "cooling off" rule, meaning those with fully insured plans would still have in-network access to MSK hospitals through Aug. 30.
That, however, does not apply to physician services and ASO plans, also known as self-funded.
As for patients in the middle of treatment, a United Healthcare spokesperson said they may qualify for "continuity of care," which provides continued in-network benefits for a specified period of time.
When asked how many patients stand to be impacted if a contract agreement isn't reached, Tracy Gosselin, a senior vice president and chief nurse executive at Memorial Sloan Kettering, said, "We have a little over 19,000 patients currently covered under the contract."
Gosselin went on to say, "Cancer is a very expensive disease to battle. You can still be fully covered, but out of pocket expenses could be travel to and from sites, could be different things related to care for your children, and they do add up."
"We will remain at the negotiating table as long as it takes"
United Healthcare released the following statement on the contract talks with Memorial Sloan Kettering.
"Our top priority is to reach an agreement with MSK that is affordable for consumers and employers. We have proposed meaningful rate increases that would continue to reimburse MSK at levels significantly higher than other National Cancer Institute-designated health systems in the New York City metro area," a spokesperson said, adding, "Unfortunately, MSK has refused to move off its demands for a 35% price hike that would increase health care costs by $469 million and directly impact self-insured employers. We will remain at the negotiating table as long as it takes to renew our relationship with MSK. We hope they join us there and provide a proposal people and employers can afford."
Memorial Sloan Kettering told CBS News New York that United Healthcare has kept rate increases for hospital services at just 1.6% per year over the past five years, far below inflation and rising costs of care.
Memorial Sloan Kettering also said it has taken extensive measures to reduce costs in recent years, including reducing staff. However, it says rising costs continue to outpace United Healthcare's reimbursements and MSK cannot continue to absorb the increases without a sustainable contract.
United Healthcare and Memorial Sloan Kettering provided updates on their websites. Please click here and here. Both are encouraging patients to use their services to help navigate the situation. CBS News New York was told mediation is happening on Friday. Both parties have expressed the priority is to reach an agreement.
United Healthcare says people enrolled in the Empire Plan are not impacted.
"Not having that access to MSK is very scary"
As a mother, Sheila Kolt's dream is to watch her children grow up.
"Sadly, I do have the BRCA gene. My whole family has had different types of cancer and passed away from cancer," Kolt said.
Those risk factors led the 45-year-old to make the difficult decision to have preventative surgeries, including a bilateral mastectomy at Memorial Sloan Kettering, last year.
"Thank goodness I did that because when they biopsied the breast tissue after the fact, they found precancerous cells," said Kolt, who now requires monitoring.
She recently received a letter from United Healthcare regarding ongoing contract negotiations with Memorial Sloan Kettering, which reads, in part, "If we're unable to reach an agreement, Memorial Sloan Kettering Cancer Center may no longer be part of your health insurance's network beginning July 1, 2025."
"It made me feel incredibly sad because MSK saved my life," Kolt said. "That means no coverage at all. I have to find new doctors. I see those bills and I say oh my God, thank God I have health insurance. It's tens of thousands of dollars."
Kolt said she just hopes her journey remains at Memorial Sloan Kettering and cancer free.
"Not having that access to MSK is very scary. It's very scary," she said.
Kolt has also been working on a documentary to share her story and encourage other women to get genetic testing.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Connected Minds: Preparing For The Cognitive Gig Economy
Connected Minds: Preparing For The Cognitive Gig Economy

Forbes

time39 minutes ago

  • Forbes

Connected Minds: Preparing For The Cognitive Gig Economy

Alex Lazovsky is a General Partner at Palo Alto Growth Capital, a VC firm based in Palo Alto, California—the heart of Silicon Valley. Imagine a future freelancer leasing out a slice of their own mind to a multinational corporation for an hour. In this speculative future, neural implants could allow human brains to plug into a shared 'neural cloud' on demand. Brainpower becomes a tradable resource—cognitive gig workers for hire. It sounds like science fiction, yet rapid advances in neurotechnology and big investments in brain-computer interfaces (BCIs) could someday bring that vision closer to reality. To understand how these advancements could affect businesses and investors, let's take a closer look at the existing technology and where it may be heading. Neurotech startups are already blurring the line between man and machine. Neuralink recently raised over $600 million in a funding round, catapulting its valuation to about $9 billion. This investor enthusiasm reflects the 'convergence of neuroscience and AI' and the belief that it could redefine how humans interact with technology. Neuralink demonstrated a human patient controlling a cursor and even browsing the internet using only their thoughts—early evidence of the transformative potential of high-bandwidth brain implants. Neuralink is not alone. Synchron, an Australian-American firm, has developed a less invasive implant that can be fed into the brain's blood vessels via the jugular vein, avoiding open brain surgery. Meanwhile, Precision Neuroscience raised over $100 million to develop an implant enabling users to control devices with thought. Venture capital is flooding into neurotech—total funding topped $2.3 billion in 2024, a more than threefold increase from just two years prior. From medical device firms to Big Tech, many investors see the brain as the next big platform. These efforts focus initially on healing—giving paralyzed patients new means to communicate or control prosthetics. But their long-term implications could reach further. Futurist Ray Kurzweil predicts that by the early 2030s, we may be able to network the human neocortex to the cloud over high-bandwidth connections. Companies like Neuralink, Paradromics and Blackrock Neurotech are already working on the technical substrate—micron-scale electrode threads and wireless interfaces—that might one day support a neural internet. Early research offers intriguing hints. In one experiment, neuroscientists connected three people's brains so they could jointly play a Tetris-like game via brain-to-brain communication. The system, dubbed BrainNet, showed that multiple minds can collaborate through a direct neural link, even across the internet. 'Our results raise the possibility of future brain-to-brain interfaces that enable cooperative problem-solving by humans using a 'social network' of connected brains,' the team noted. If human brains become nodes on a neural network, a new marketplace may emerge around cognitive capacity on demand. Just as cloud computing turned computing power into a utility, a 'cognitive gig economy' could turn mental work into a cloud service. Individuals might rent out spare brain bandwidth in exchange for payment, performing data analysis, pattern recognition or creative brainstorming via direct neural link. A company of the future might hire 1,000 connected minds for an hour to crowdsource a tough research problem—not by convening a meeting but by literally tapping into distributed human brains through the neural cloud. Such scenarios sound surreal, yet they extrapolate from trends already in motion. Automation and AI are transforming traditional jobs, but paradoxically, human intelligence may become a commodity itself—outsourced, fractional and ubiquitous. Knowledge workers could one day freelance their neurons, akin to Uber drivers lending their cars or time. A 'Brain-as-a-Service' industry might arise, with exchanges or platforms matching those who need cognitive help with those willing to provide it via neural link. For all its promise, this cognitive gig economy raises profound ethical and societal questions. If your brain is connected to the cloud, who safeguards your mental privacy? Brain data can reveal deeply personal information—emotions, memories, even subconscious biases. Questions of cognitive liberty loom large: Would people feel pressured to get brain implants to compete in the future job market? Could employers favor workers who can literally 'multitask' with an AI coprocessor in their heads? There's also the risk of neuro-exploitation. In a world where disadvantaged individuals might rent out their mental processing to make ends meet, new forms of inequality could emerge. The cognitive gig economy might empower people to earn money with their minds, but it could also commoditize human cognition, treating thoughts as labor units. If the 'main products of the 21st-century economy' indeed become 'bodies, brains and minds,' as Yuval Noah Harari suggests, society must grapple with how to value and protect those minds in the marketplace. What steam power and electricity were to past centuries, neural interfaces might be to this one—a general-purpose technology that could transform economies and lives. For forward-looking investors and executives, I recommend keeping a close eye on your head because it may also be your next capital asset. If the next era becomes one of connected minds, those who can balance bold innovation with human-centered ethics might shape a future where brainpower for hire could truly benefit humanity. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?

Dog on Colorado's Anschutz Medical Campus leading way on novel obsessive-compulsive disorder therapy treatment
Dog on Colorado's Anschutz Medical Campus leading way on novel obsessive-compulsive disorder therapy treatment

CBS News

time39 minutes ago

  • CBS News

Dog on Colorado's Anschutz Medical Campus leading way on novel obsessive-compulsive disorder therapy treatment

It has become common for dogs to be used for a variety of behavioral health solutions, including those like post-traumatic stress disorder, for instance. But at the University of Colorado Anschutz Medical Campus, there is a single dog that is being used in a rather unique way: helping patients with obsessive compulsive disorder, or OCD, manage their symptoms. Cate Rush, a social work fellow who works on the campus, has had Otis the Bernese Mountain Dog since her junior year of her undergraduate studies. He's helped in her in a variety of ways throughout her adult life, and she's now using him to help her patients as well. Cate Rush with Otis CBS "I just feel like it's so special that he's able to do something that humans cannot," she said. Otis is a trained therapy dog but works with a specific set of clients. Most of the patients that come see Cate have OCD. "Therapy dogs aren't commonly used for OCD so it's been a bit of a learning experience how to use him," she said. The research on the use of dogs for OCD patients is still evolving, as is most of the research around therapy dogs in general. It's only been since the turn of the 2000s that having dogs used as aids for behavioral health solutions has become more common. But it's rare to see one that is working with OCD patients. Otis is the only dog of his kind on the medical campus in Aurora. Obsessive-compulsive disorder currently affects 2.5% of the United States population and can be treated with what is called exposure and response prevention therapy, or ERPT. It usually involves exposing patients to things that trigger their obsessive behaviors while giving them tools to help prevent them from engaging in their typical compulsions. A 2010 study by the University of Pennsylvania, cited in the National Institute of Health, showed that ERPT can significantly reduce OCD symptoms in up to 80% of patients. CBS That's where Otis comes in. He can help in a variety of ways, as a supportive and helpful sidekick to those being exposed to triggering things or situations or, in some cases, being a walking exposure therapy himself. "There are a lot of patients who might have contamination fears," Rush said, "They can use him in exposure so I've had patients touch his paws or rub his belly." "I had a patient and one of her final exposures in the IOP -- the intensive outpatient program -- was to high five Otis and that was really sweet," she added. While Otis isn't part of any official research at Anschutz just yet, his presence signals an evolving approach to behavioral health solutions. One wag at a time.

Anixa Biosciences to Host an Investor Webcast on June 26, 2025
Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Yahoo

timean hour ago

  • Yahoo

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

SAN JOSE, Calif., June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT. During the webcast, Dr. Amit Kumar, Anixa's Chairman and CEO, will conduct an introductory presentation that will cover key aspects of Anixa's business including an overview of the Company's therapeutic portfolio, its business strategy, market opportunity and near-term milestones. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal. To listen to the webcast or to ask questions during the live event, please pre-register at the following link: An archived version of the webcast and presentation will be available on the Company's website, About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store